Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 3Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2330Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1782Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 935Prednisone 925Cetuximab 921Lenalidomide 916Trastuzumab 901

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × bisantrene × Clear all
NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown
29 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05456269 2023-10-03

BISECT

Racura Oncology Ltd

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03820908 2020-08-07

Bisantrene for Relapsed /Refractory AML

Sheba Medical Center

Phase 2 Completed
10 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡